These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 30257990

  • 1. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
    Ryan MR, Sohl CD, Luo B, Anderson KS.
    Mol Cancer Res; 2019 Feb; 17(2):532-543. PubMed ID: 30257990
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
    Sohl CD, Ryan MR, Luo B, Frey KM, Anderson KS.
    ACS Chem Biol; 2015 May 15; 10(5):1319-29. PubMed ID: 25686244
    [Abstract] [Full Text] [Related]

  • 6. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R, Willems SM.
    Clin Cancer Res; 2016 Aug 01; 22(15):3884-93. PubMed ID: 26936917
    [Abstract] [Full Text] [Related]

  • 7. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR.
    J Thorac Oncol; 2019 Oct 01; 14(10):1847-1852. PubMed ID: 31195180
    [Abstract] [Full Text] [Related]

  • 8. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
    Cowell JK, Qin H, Hu T, Wu Q, Bhole A, Ren M.
    Int J Cancer; 2017 Nov 01; 141(9):1822-1829. PubMed ID: 28646488
    [Abstract] [Full Text] [Related]

  • 9. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
    Peng R, Chen Y, Wei L, Li G, Feng D, Liu S, Jiang R, Zheng S, Chen Y.
    Gastric Cancer; 2020 Nov 01; 23(6):988-1002. PubMed ID: 32617693
    [Abstract] [Full Text] [Related]

  • 10. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
    Luo H, Quan J, Xiao H, Luo J, Zhang Q, Pi G, Ye Y, He R, Liu Y, Su X, Zhao L, Wang G.
    Oncol Rep; 2018 May 01; 39(5):2270-2278. PubMed ID: 29517107
    [Abstract] [Full Text] [Related]

  • 11. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Kenichi Suda, Jiang T, Zhou C, Heasley LE, Hirsch FR.
    Clin Lung Cancer; 2018 Sep 01; 19(5):450-456. PubMed ID: 30146263
    [Abstract] [Full Text] [Related]

  • 12. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H, Ebi H, Kitai H, Nanjo S, Kita K, Huynh TG, Ooi A, Faber AC, Mino-Kenudson M, Yano S.
    Oncogene; 2016 Jul 07; 35(27):3587-97. PubMed ID: 26549034
    [Abstract] [Full Text] [Related]

  • 13. Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.
    Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E.
    PLoS One; 2016 Jul 07; 11(2):e0149628. PubMed ID: 26905262
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.
    Phanhthilath N, Hakim S, Su C, Liu A, Subramonian D, Lesperance J, Zage PE.
    Invest New Drugs; 2020 Dec 07; 38(6):1677-1686. PubMed ID: 32436058
    [Abstract] [Full Text] [Related]

  • 15. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, Hampson M, Gavine PR, Cook SJ.
    Oncogene; 2013 Jun 20; 32(25):3059-70. PubMed ID: 22869148
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S, Shao L, Castro P, Coleman I, Nelson PS, Smith PD, Davies BR, Ittmann M.
    Oncotarget; 2017 Jan 24; 8(4):6179-6192. PubMed ID: 28008155
    [Abstract] [Full Text] [Related]

  • 20. Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
    Vad-Nielsen J, Gammelgaard KR, Daugaard TF, Nielsen AL.
    Lung Cancer; 2019 Jun 24; 132():132-140. PubMed ID: 31097086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.